Recherche
-
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial
(PLoS Pathogens. vol. 16, n° 6, pp. e1008522, 2020-06-26)Article de revueLibre accès -
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
(Nature Communications. vol. 12, n° 1, pp. 5215, 2021-09-01)Article de revueLibre accès -
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
(eLife. vol. 11, pp. e75427, 2022-07-08)Article de revueLibre accès -
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
(PLoS Medicine. vol. 19, n° 1, 2022-01-11)Article de revueLibre accès -
Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
(EBioMedicine. vol. 80, 2022-06)Article de revueLibre accès -
Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals
(Frontiers in Immunology. vol. 10, 2019-04-24)Article de revueLibre accès -
CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death
(iScience. vol. 24, n° 7, pp. 102711, 2021-07-23)Article de revueLibre accès